PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
60.05%
R&D growth while CRVO reduces spending. John Neff would investigate strategic advantage.
231.77%
G&A growth above 1.5x CRVO's 2.86%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
121.69%
Operating expenses growth while CRVO reduces costs. John Neff would investigate differences.
-100.00%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
D&A reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine efficiency.
-127.89%
EBITDA decline while CRVO shows 26.76% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-121.69%
Operating income decline while CRVO shows 26.76% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-17.94%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-139.60%
Pre-tax income decline while CRVO shows 27.02% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-139.60%
Net income decline while CRVO shows 27.02% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-131.82%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-131.82%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.